Galena Biopharma Reports Fourth Quarter and Year End 2013 Results

[at noodls] – Successful Abstral launch in Q4 2013 resulted in $2.5 million in net revenue consistent with guidance of $1.5 to $3 million. Galena is increasing its 2014 Abstral net revenue estimates to $11 to $15 million … more

View todays social media effects on RXII

View the latest stocks trending across Twitter. Click to view dashboard

See who RXi is hiring next, click here to view